Related Experiment Videos
Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin
Insights
Calcium fosfomycin effectively treated acute gastroenterocolitis in neonates caused by enteropathogenic E. coli. This antibiotic showed favorable clinical and bacteriological outcomes with no observed toxicity in infants.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Neonatal acute gastroenterocolitis is a significant health concern.
- Enteropathogenic Escherichia coli (E. coli) is a common cause of neonatal infections.
- Effective and safe antibiotic treatments are crucial for neonates.
Purpose of the Study:
- To evaluate the efficacy and safety of calcium salt of fosfomycin in treating neonatal acute gastroenterocolitis.
- To determine the minimal inhibitory concentration (MIC) of enteropathogenic E. coli against fosfomycin.
- To assess clinical and bacteriological outcomes and potential toxicity.
Main Methods:
- A study involving 43 neonates with acute gastroenterocolitis caused by enteropathogenic E. coli.
- Oral administration of calcium fosfomycin at dosages of 150-200 mg/kg/day every 8 hours for 4 days.
- Evaluation of clinical and bacteriological responses, and monitoring for adverse effects.
Main Results:
- Favorable clinical evolution observed in 38 out of 43 neonates (88%).
- Successful bacteriological eradication achieved in 30 out of 43 neonates (70%).
- No toxic alterations attributed to fosfomycin were observed in any treated neonates.
Conclusions:
- Calcium fosfomycin is an effective and safe treatment option for neonatal acute gastroenterocolitis caused by enteropathogenic E. coli.
- The antibiotic demonstrated good clinical and bacteriological efficacy with a favorable safety profile.
- Further research may explore the impact on gut flora and long-term outcomes.
Abstract:
The effect of calcium salt of fosfomycin in the treatment of 43 neonates suffering from acute gastroenterocolitis produced by enteropathogenic E. coli is evaluated. The minimal inhibitory concentration of these E. coli was, generally, lower than 128 mug/ml. Dosages of 150-200 mg/kg body weight/day were administered orally every 8 h. This treatment lasted for 4 days only. Clinical evolution was favorable in 38 (88%) babies and bacteriological evolution in 30 (70%). In eight cases a different flora to the initial was selected during the treatment with fosfomycin. None of the cases treated showed any toxic alteration attributed to the antibiotic.